| Reaction Details |
|---|
 | Report a problem with these data |
| Target | 5-hydroxytryptamine receptor 2B |
|---|
| Ligand | BDBM82272 |
|---|
| Substrate/Competitor | n/a |
|---|
| Ki | 630.95±n/a nM |
|---|
| Comments | PDSP_1671 |
|---|
| Citation |  Bonhaus, DW; Weinhardt, KK; Taylor, M; DeSouza, A; McNeeley, PM; Szczepanski, K; Fontana, DJ; Trinh, J; Rocha, CL; Dawson, MW; Flippin, LA; Eglen, RM RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist. Neuropharmacology36:621-9 (1997) [PubMed] Article |
|---|
| More Info.: | Get all data from this article |
|---|
| |
| 5-hydroxytryptamine receptor 2B |
|---|
| Name: | 5-hydroxytryptamine receptor 2B |
|---|
| Synonyms: | 5-HT-2B | 5-HT2B | 5-hydroxytryptamine (serotonin) receptor 2B [Homo sapiens] | 5-hydroxytryptamine receptor 2B (5-HT2B) | 5-hydroxytryptamine receptor 2C (5HT2C) | 5HT2B_HUMAN | HTR2B | Serotonin (5-HT3) receptor | Serotonin 2b (5-HT2b) receptor | Serotonin Receptor 2B |
|---|
| Type: | G Protein-Coupled Receptor (GPCR) |
|---|
| Mol. Mass.: | 54312.47 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Receptor binding assays were performed using human clone stably expressed in CHO cells. |
|---|
| Residue: | 481 |
|---|
| Sequence: | MALSYRVSELQSTIPEHILQSTFVHVISSNWSGLQTESIPEEMKQIVEEQGNKLHWAALL
ILMVIIPTIGGNTLVILAVSLEKKLQYATNYFLMSLAVADLLVGLFVMPIALLTIMFEAM
WPLPLVLCPAWLFLDVLFSTASIMHLCAISVDRYIAIKKPIQANQYNSRATAFIKITVVW
LISIGIAIPVPIKGIETDVDNPNNITCVLTKERFGDFMLFGSLAAFFTPLAIMIVTYFLT
IHALQKKAYLVKNKPPQRLTWLTVSTVFQRDETPCSSPEKVAMLDGSRKDKALPNSGDET
LMRRTSTIGKKSVQTISNEQRASKVLGIVFFLFLLMWCPFFITNITLVLCDSCNQTTLQM
LLEIFVWIGYVSSGVNPLVYTLFNKTFRDAFGRYITCNYRATKSVKTLRKRSSKIYFRNP
MAENSKFFKKHGIRNGINPAMYQSPMRLRSSTIQSSSIILLDTLLLTENEGDKTEEQVSY
V
|
|
|
|---|
| BDBM82272 |
|---|
| n/a |
|---|
| Name | BDBM82272 |
|---|
| Synonyms: | SB 200646 | SB200646a |
|---|
| Type | n/a |
|---|
| Emp. Form. | C15H14N4O |
|---|
| Mol. Mass. | 266.2979 |
|---|
| SMILES | Cn1ccc2cc(NC(=O)Nc3cccnc3)ccc12 |
|---|
| Structure | 
|
|---|
Search and Browse
